Webinar: HIV-1 genotyping targeting integrase
We discuss how Sanger sequencing addresses local surveillance needs in various communities and hear thoughts regarding the future trends in HIV-1 genotyping for genetic and epidemiologic surveillance.
Remarkable progress has been made since 2010 in the global fight to end the HIV epidemic. However, we still witness more than 1.5 M new HIV infections per year globally. Over the last ten years, we have seen that with resource availability and access to care, it is possible to significantly impact HIV transmission and AIDS deaths. Achievement of the UNAIDS 2030 95-95-95 Fast-Track Targets includes access to high quality, HIV-1 viral load testing, and mitigation of emerging antiretroviral mutations that confer drug resistance. We are proud to offer both testing solutions to healthcare communities to fight HIV.
Product availability varies per country. Please contact your local sales representative for more details.
Want to use our solutions? Contact us for details on our limited time offer. |
One of the problems with the HIV virus is that it mutates very rapidly, rendering available antiretroviral therapies ineffective in suppressing the disease. Up to 10% of adults starting HIV treatment experience drug resistance to certain classes of drugs, and nearly 50% of infants born to mothers with HIV experience resistance to at least one class of drug. HIV now shows development of drug resistance to even the newer, highly effective integrase class of drugs.
Our newly introduced Applied Biosystems HIV-1 Genotyping Kit with Integrase helps to detect and monitor drug resistance mutations in three main antiretroviral drug classes across a broad range of viral subtypes, helping to ensure that the right drug is delivered to the right patient at the right time. This kit—offered at access pricing—directly responds to the WHO’s recommendation that HIV drug resistance prevention, surveillance monitoring, and response be integrated into every national HIV program.
The TaqPath Seq HIV-1 Genotyping Kit harnesses gold standard Sanger sequencing technology to amplify and reliably sequence the diverse and rapidly evolving HIV-1 virus.
Survey HIVDR mutations with the CDC
Having an accurate and sensitive test for HIV-1 genetic variants that resist common antiretroviral therapeutics is critical for epidemiologic and genetic surveillance studies. Here, a scientist from the United States Centers for Disease Control (CDC) discusses the CDC’s experience investigating this assay for monitoring drug resistance mutations in the protease, reverse transcriptase, and integrase regions of the pol gene.
HIV-1 amplification and sequencing reagents in one kit
Help improve lot-to-lot performance, quality, and timeliness of results.
The TaqPath Seq HIV-1 Genotyping Kit features:
- A standardized, cost-effective assay in a scalable workflow
- A total workflow of about 20 hours for processing extracted viral RNA from EDTA plasma or DBS to results, with a total hands-on time of ~4.5 hours
- The ability to detect mutations in the protease, reverse transcriptase, and integrase regions of the HIV-1 pol gene in subtypes A, B, C, D, F, G, CRF01_AE, CRF02_AG, and CRF06_CPX
Nucleic acids from plasma or dried blood spot (DBS) samples are extracted.
After sample processing and RNA extraction, samples undergo an initial reverse transcription + PCR, followed by a second nested PCR step for mutation targets of interest. The TaqPath Seq HIV-1 Genotyping Kit includes the RT-PCR master mix, the nested PCR master mix, and necessary positive and negative controls that allow for a simple, streamlined workflow as you move into your cleanup and sequencing steps.
Once you confirm and clean up your targeted PCR product, the remainder of the TaqPath Seq HIV-1 Genotyping Kit is used for cycle sequencing. Included in this kit are the forward/reverse pre-formulated sequencing mixes for the targets of interest.
Analyze the sequencing traces by exporting the AB1 files from the 3500 Series or 3500 Dx Series Genetic Analyzer for use in downstream analysis and reporting software.
Note: To learn more about available commercial software, consult the WHO documents listed in “Related documentation" on page 48 of the Instructions for Use.
Nucleic acids from plasma or dried blood spot (DBS) samples are extracted.
After sample processing and RNA extraction, samples undergo an initial reverse transcription + PCR, followed by a second nested PCR step for mutation targets of interest. The TaqPath Seq HIV-1 Genotyping Kit includes the RT-PCR master mix, the nested PCR master mix, and necessary positive and negative controls that allow for a simple, streamlined workflow as you move into your cleanup and sequencing steps.
Once you confirm and clean up your targeted PCR product, the remainder of the TaqPath Seq HIV-1 Genotyping Kit is used for cycle sequencing. Included in this kit are the forward/reverse pre-formulated sequencing mixes for the targets of interest.
Analyze the sequencing traces by exporting the AB1 files from the 3500 Series or 3500 Dx Series Genetic Analyzer for use in downstream analysis and reporting software.
Note: To learn more about available commercial software, consult the WHO documents listed in “Related documentation" on page 48 of the Instructions for Use.
Access pricing available to eligible customers. Contact us to learn more.
Quantitative and qualitative PCR testing of HIV-1 viral levels in blood is an essential tool in the care and management of persons living with HIV. Frequent monitoring of HIV-1 viral load can serve as an early, first-step indication of the development of drug resistance.
Applied Biosystems TaqPath Menu | GeneProof® HIV Type 1 (HIV-1) Diagnostic PCR Kit features:
Dual target detection
|
Contamination reduction
|
Qualitative and quantitative detection
|
Easy-to-use concept
|
Device compatibility
|
|
Resources
Resources
HIV-1 resistance testing
ASLM content
HIV-1 webinar
AIDS 2022 satellite symposium
HIV-1 viral load testing
For In Vitro Diagnostic Use. Not available in all countries.
Style Sheet for Global Design System